Market Overview:
The global polypeptide drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for polypeptide drugs owing to their better efficacy and safety profile as compared to small molecule drugs, and growing investments by pharmaceutical companies in R&D for the development of novel polypeptide drugs. Based on type, the global polypeptide drug market can be segmented into injection, nasal administration, lung administration, oral administration, and transdermal administration. Injection is currently the most popular route of delivery for polypeptide drugs and is expected to maintain its dominance during the forecast period. However, nasal administration is projected to grow at a higher CAGR than other routes due to its advantages such as ease of use and lower incidence of side effects as compared with other routes.
Product Definition:
A polypeptide drug is a peptide or protein molecule that is used as a medication. Polypeptides are important because they can be used to treat a variety of diseases and conditions, including cancer, diabetes, and heart disease. They are also used as immunomodulators and vaccines.
Injection:
Injection is a medical procedure wherein the active ingredients of drugs are introduced into the blood vessels through needles. The most common route of administration is by intravenous injection, which involves introducing the drug into a vein.
The global polypeptide industry has witnessed significant growth over recent years owing to rising incidences of chronic diseases such as cancer, arthritis and diabetes coupled with increasing demand for efficient and rapid acting therapeutics.
Nasal Administration:
Nasal administration is the most common route of drug delivery. It allows drugs to be delivered directly into the nose, which is then transported by nasal mucosa cells to the brain. This mode of drug delivery has several advantages over other routes of administration such as oral and intravenous; it minimizes first pass metabolism, thereby increasing bioavailability and absorption rate.
Application Insights:
The immunity regulating medicines (allergy infection and immune) segment dominated the global polypeptide drug market in 2017. This is attributed to the rising prevalence of chronic diseases, such as allergy and infections. According to WHO, globally around 35% of adults suffer from allergic rhinitis while 20-30% have asthma. In addition, over 300 million people are infected with tuberculosis annually while 1 billion people get sick due to influenza every year worldwide. These statistics indicate that a large number of patients are suffering from chronic conditions which require regular medication throughout their life course which is anticipated to drive demand for polypeptide drugs during the forecast period.
Regional Analysis:
North America dominated the global polypeptide drug market with a revenue share of over 35.0% in 2017. This is attributed to the presence of key players such as Pfizer, Inc.; Merck & Co., Inc.; and Sanofi in this region. Moreover, factors such as increasing prevalence of chronic diseases and rising demand for immunosuppressants are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as growing geriatric population coupled with an increase in lifestyle-associated diseases that require long term treatment; improving healthcare facilities; and economic development leading to high disposable income levels among individuals enabling them access better healthcare services resulting into higher adoption rates for polypeptide drugs compared to other therapies across various regions globally (North America, Europe). The Middle East & Africa also have a large patient pool which needs effective treatment options thus driving product demand across this region (Africa).
Growth Factors:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is expected to drive the demand for polypeptide drugs over the forecast period.
- Rising geriatric population is also anticipated to boost the market growth as this population is more susceptible to chronic diseases.
- Growing research and development activities for novel polypeptide drugs are expected to provide opportunities for market expansion.
- Technological advancements in drug delivery systems are likely to propel the demand for polypeptide drugs in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Polypeptide Drug Market Research Report
By Type
Injection, Nasal Administration, Lung Administration, Oral Administration, Transdermal Administration
By Application
Immunity Regulating Medicine (Allergy Infection and Immune), Digestive System Drugs (Gastrointestinal Type), Bone and Connective Tissue Types (Thyroid hormones Drug), Gynecologic or Obstetric Drug, Tumor Drug, Urinary System Drug, Metabolic Drug (Insulin and Other Hypoglycemic Agents)
By Companies
Novartis, Merck Serono, Ferring Pharmaceuticals, Ipsen PHarma Biotech, Lilly, Asahi Kasei, AstraZeneca, SciClone Pharmaceuticals, Takeda, Roche, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Polypeptide Drug Market Report Segments:
The global Polypeptide Drug market is segmented on the basis of:
Types
Injection, Nasal Administration, Lung Administration, Oral Administration, Transdermal Administration
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunity Regulating Medicine (Allergy Infection and Immune), Digestive System Drugs (Gastrointestinal Type), Bone and Connective Tissue Types (Thyroid hormones Drug), Gynecologic or Obstetric Drug, Tumor Drug, Urinary System Drug, Metabolic Drug (Insulin and Other Hypoglycemic Agents)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Merck Serono
- Ferring Pharmaceuticals
- Ipsen PHarma Biotech
- Lilly
- Asahi Kasei
- AstraZeneca
- SciClone Pharmaceuticals
- Takeda
- Roche
- Sanofi
Highlights of The Polypeptide Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Nasal Administration
- Lung Administration
- Oral Administration
- Transdermal Administration
- By Application:
- Immunity Regulating Medicine (Allergy Infection and Immune)
- Digestive System Drugs (Gastrointestinal Type)
- Bone and Connective Tissue Types (Thyroid hormones Drug)
- Gynecologic or Obstetric Drug
- Tumor Drug
- Urinary System Drug
- Metabolic Drug (Insulin and Other Hypoglycemic Agents)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Polypeptide Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A polypeptide drug is a type of medication that is composed of many amino acids. These drugs are often used to treat diseases or conditions because they can interact with the body's natural proteins to produce specific effects.
Some of the major companies in the polypeptide drug market are Novartis, Merck Serono, Ferring Pharmaceuticals, Ipsen PHarma Biotech, Lilly, Asahi Kasei, AstraZeneca, SciClone Pharmaceuticals, Takeda, Roche, Sanofi.
The polypeptide drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Polypeptide Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Polypeptide Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Polypeptide Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Polypeptide Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Polypeptide Drug Market Size & Forecast, 2018-2028
4.5.1 Polypeptide Drug Market Size and Y-o-Y Growth
4.5.2 Polypeptide Drug Market Absolute $ Opportunity
Chapter 5 Global Polypeptide Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Polypeptide Drug Market Size Forecast by Type
5.2.1 Injection
5.2.2 Nasal Administration
5.2.3 Lung Administration
5.2.4 Oral Administration
5.2.5 Transdermal Administration
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Polypeptide Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Polypeptide Drug Market Size Forecast by Applications
6.2.1 Immunity Regulating Medicine (Allergy Infection and Immune)
6.2.2 Digestive System Drugs (Gastrointestinal Type)
6.2.3 Bone and Connective Tissue Types (Thyroid hormones Drug)
6.2.4 Gynecologic or Obstetric Drug
6.2.5 Tumor Drug
6.2.6 Urinary System Drug
6.2.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Polypeptide Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Polypeptide Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Polypeptide Drug Analysis and Forecast
9.1 Introduction
9.2 North America Polypeptide Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Polypeptide Drug Market Size Forecast by Type
9.6.1 Injection
9.6.2 Nasal Administration
9.6.3 Lung Administration
9.6.4 Oral Administration
9.6.5 Transdermal Administration
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Polypeptide Drug Market Size Forecast by Applications
9.10.1 Immunity Regulating Medicine (Allergy Infection and Immune)
9.10.2 Digestive System Drugs (Gastrointestinal Type)
9.10.3 Bone and Connective Tissue Types (Thyroid hormones Drug)
9.10.4 Gynecologic or Obstetric Drug
9.10.5 Tumor Drug
9.10.6 Urinary System Drug
9.10.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Polypeptide Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Polypeptide Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Polypeptide Drug Market Size Forecast by Type
10.6.1 Injection
10.6.2 Nasal Administration
10.6.3 Lung Administration
10.6.4 Oral Administration
10.6.5 Transdermal Administration
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Polypeptide Drug Market Size Forecast by Applications
10.10.1 Immunity Regulating Medicine (Allergy Infection and Immune)
10.10.2 Digestive System Drugs (Gastrointestinal Type)
10.10.3 Bone and Connective Tissue Types (Thyroid hormones Drug)
10.10.4 Gynecologic or Obstetric Drug
10.10.5 Tumor Drug
10.10.6 Urinary System Drug
10.10.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Polypeptide Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Polypeptide Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Polypeptide Drug Market Size Forecast by Type
11.6.1 Injection
11.6.2 Nasal Administration
11.6.3 Lung Administration
11.6.4 Oral Administration
11.6.5 Transdermal Administration
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Polypeptide Drug Market Size Forecast by Applications
11.10.1 Immunity Regulating Medicine (Allergy Infection and Immune)
11.10.2 Digestive System Drugs (Gastrointestinal Type)
11.10.3 Bone and Connective Tissue Types (Thyroid hormones Drug)
11.10.4 Gynecologic or Obstetric Drug
11.10.5 Tumor Drug
11.10.6 Urinary System Drug
11.10.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Polypeptide Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Polypeptide Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Polypeptide Drug Market Size Forecast by Type
12.6.1 Injection
12.6.2 Nasal Administration
12.6.3 Lung Administration
12.6.4 Oral Administration
12.6.5 Transdermal Administration
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Polypeptide Drug Market Size Forecast by Applications
12.10.1 Immunity Regulating Medicine (Allergy Infection and Immune)
12.10.2 Digestive System Drugs (Gastrointestinal Type)
12.10.3 Bone and Connective Tissue Types (Thyroid hormones Drug)
12.10.4 Gynecologic or Obstetric Drug
12.10.5 Tumor Drug
12.10.6 Urinary System Drug
12.10.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Polypeptide Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Polypeptide Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Polypeptide Drug Market Size Forecast by Type
13.6.1 Injection
13.6.2 Nasal Administration
13.6.3 Lung Administration
13.6.4 Oral Administration
13.6.5 Transdermal Administration
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Polypeptide Drug Market Size Forecast by Applications
13.10.1 Immunity Regulating Medicine (Allergy Infection and Immune)
13.10.2 Digestive System Drugs (Gastrointestinal Type)
13.10.3 Bone and Connective Tissue Types (Thyroid hormones Drug)
13.10.4 Gynecologic or Obstetric Drug
13.10.5 Tumor Drug
13.10.6 Urinary System Drug
13.10.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Polypeptide Drug Market: Competitive Dashboard
14.2 Global Polypeptide Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Merck Serono
14.3.3 Ferring Pharmaceuticals
14.3.4 Ipsen PHarma Biotech
14.3.5 Lilly
14.3.6 Asahi Kasei
14.3.7 AstraZeneca
14.3.8 SciClone Pharmaceuticals
14.3.9 Takeda
14.3.10 Roche
14.3.11 Sanofi
